Patient-derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcinoma
Menée à partir d'échantillons tumoraux prélevés sur 67 patients atteints d'un adénocarcinome canalaire du pancréas, cette étude démontre la possibilité de maintenir en culture des organoïdes et met en évidence une association entre leur sensibilité thérapeutique et les résultats cliniques
Pancreatic ductal adenocarcinoma (PDAC) ranks among the most lethal cancers, with only 20% of patients qualifying for curative treatment at diagnosis. Three-dimensional tumor organoids capturing patient-specific features of PDAC serve as a valuable disease model. We employed this technology to assess drug sensitivities of patient-derived tumor organoids to clinically relevant drugs and combinations, evaluated culture success rates, and correlated in vitro data with clinicopathological and follow-up information. Tumor organoid cultures were established from PDAC patients undergoing surgical resection (or liver biopsy) and follow-up at a single medical center. Patient-derived cultures displaying sustained growth were analyzed regarding their molecular subtype and utilized for functional drug sensitivity testing (f-DST). Correlative analyses of our PDAC patient cohort (n = 67; n = 42 patients with curative tumor resection and n = 25 palliative patients) revealed a link between tumor organoid growth and reduced patient survival. Furthermore, drug sensitivity profiles (obtained of 10 patient-derived cultures) revealed notable inter-individual differences and mirrored clinical responses to administered drug therapies. f-DST was applicable across tumor organoid cultures of both classical and basal subtype, according to the Purity Independent Subtyping of Tumors (PurIST) classifier. This pilot study confirms the feasibility of deriving and maintaining tumor organoid cultures from heterogeneous samples. Cultures displaying sustained proliferation correlated positively with advanced-stage tumors (Tumour, Node, Metastasis (UICC) stages III and IV). Individual patient case analyses integrating in vitro drug sensitivity profiles with clinical follow-up data suggest that f-DST using tumor organoids could guide future therapeutic strategies. In summary, tumor organoids offer insights into patient-specific responses to treatment, highlighting the potential of precision medicine in managing this challenging cancer.
International Journal of Cancer , article en libre accès 2025